Nadifloxacin

Nadifloxacin is a fluoroquinolone antibiotic.¹ It is active against clinical isolates of S. aureus, coagulase-negative staphylococci, P. acnes, and P. granulosum (MIC₅₀s = 0.03, 0.06, 0.25, and 0.125 mg/L, respectively). Nadifloxacin inhibits the activities of DNA gyrase and topoisomerase IV (IC₅₀s = 8.83 and 3.22 mg/L, respectively, for the S. aureus enzymes).² Nadifloxacin (30 µg/ml) inhibits P. acnes-induced increases in the production of IFN-γ, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs), as well as reduces P. acnes-induced increases in the production of IL-8 and IL-6 in isolated human keratinocytes.³ Topical application of a cream containing nadifloxacin (1%) reduces the number of skin lesion colony forming units (CFUs) in a mouse model of burn wounds infected with S. aureus or P. acnes.² Formulations containing nadifloxacin have been used in the treatment of acne vulgaris.

WARNING This product is not for human or veterinary use.

1. Vogt, K., Hermann, J., Blume, U., et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur. J. Clin. Microbiol. Infect. Dis. 11(10), 943-945 (1992).

2. Yamakawa, T., Mitsuyama, J., and Hayashi, K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J. Antimicrob. Chemother. 49(3), 455-465 (2002).

3. Kuwahara, K., Kitazawa, T., Kitagaki, H., et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J. Dermatol. Sci. 38(1), 47-55 (2005).